Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples
Open Access
- 4 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Cell cycle control drives cancer progression and treatment response in high grade serous ovarian carcinoma (HGSOC). MYBL2 (encoding B-Myb), an oncogene with prognostic significance in several cancers, is highly expressed in most HGSOC cases; however, the clinical significance of B-Myb in this disease has not been well-characterized. B-Myb is associated with cell proliferation through formation of the MMB (Myb and MuvB core) protein complex required for transcription of mitotic genes. High B-Myb expression disrupts the formation of another transcriptional cell cycle regulatory complex involving the MuvB core, DREAM (DP, RB-like, E2F, and MuvB), in human cell lines. DREAM coordinates cell cycle dependent gene expression by repressing over 800 cell cycle genes in G0/G1. Here, we take a bioinformatics approach to further evaluate the effect of B-Myb expression on DREAM target genes in HGSOC and validate our cellular model with clinical specimens. We show that MYBL2 is highly expressed in HGSOC and correlates with expression of DREAM and MMB target genes in both The Cancer Genome Atlas (TCGA) as well as independent analyses of HGSOC primary tumors (N = 52). High B-Myb expression was also associated with poor overall survival in the TCGA cohort and analysis by a DREAM target gene expression signature yielded a negative impact on survival. Together, our data support the conclusion that high expression of MYBL2 is associated with deregulation of DREAM/MMB-mediated cell cycle gene expression programs in HGSOC and may serve as a prognostic factor independent of its cell cycle role. This provides rationale for further, larger scale studies aimed to determine the clinical predictive value of the B-Myb gene expression signature for treatment response as well as patient outcomes.Keywords
This publication has 42 references indexed in Scilit:
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastJNCI: Journal of the National Cancer Institute, 2013
- The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding MechanismMolecular and Cellular Biology, 2013
- curatedOvarianData: clinically annotated data for the ovarian cancer transcriptomeDatabase: The Journal of Biological Databases and Curation, 2013
- The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expressionGenes & Development, 2012
- Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-DamagePLOS ONE, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assemblyGenes & Development, 2011
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2Cancer Cell, 2009
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006